Prognose des primären Sjögren-Syndroms unter besonderer Berücksichtigung des Lymphomrisikos

Zusammenfassung

Das primäre Sjögren-Syndrom ist eine chronische Autoimmunepithelitis, die Speichel-, Tränen- und andere exokrine Drüsen befällt. Extraglanduläre Manifestationen sind häufig, jedoch selten bedrohlich. Die Sicca-Symptomatik ist häufig chronisch progredient, wobei die Progredienz am stärksten im Zeitraum von der Erstmanifestation bis zur Diagnosestellung zu sein scheint. Das klinische Gesamtbild wie auch die individuelle serologische Konstellation einschließlich der Manifestationen ist sehr variabel und hat sich in Langzeituntersuchungen vom Zeitpunkt der Diagnosestellung an als sehr stabil erwiesen, sie verändern sich kaum im Vergleich zum Zeitpunkt der Diagnosestellung. Letzteres erlaubt möglicherweise eine Risikoabschätzung bereits bei Diagnosestellung. Die Lebenserwartung der Erkrankten ist mit Ausnahme einer kleinen Patientengruppe nicht reduziert. Das primäre Sjögren-Syndrom prädisponiert mehr als alle anderen Kollagenosen zu Malignomen des hämatopoetischen Systems, insbesondere treten gehäuft Non-Hodgkin-Lymphome auf. Die vorliegende Arbeit beleuchtet unterschiedliche Aspekte des Langzeitverlaufs im Hinblick auf Prognose, Lebenserwartung und Lymphomgefährdung. Daraus abgeleitet werden eine Risikoeinschätzung und die resultierende Intensität der Langzeitüberwachung der Patienten vorgeschlagen.

Abstract

Primary Sjögren’s syndrome is a chronic autoimmune epithelitis which affects salivary, lacrimal and other exocrine glands. Extraglandular manifestations are common but seldom dangerous and threatening. The sicca symptoms are often slowly chronic-progressive whereby the progress seems to be most striking during the period between first manifestation and confirmation of diagnosis. The clinical course as well as the serological constellations and the extraglandular manifestations seem to be rather variable but stable during the long-term follow-up from the time of diagnostic confirmation onwards with no drastic changes compared with the status when the diagnosis was fixed. This probably allows an initial prognostic stratification at the time of the first consultation. The life expectancy of patients with Sjögren’s syndrome is, except for a minority of patients, as good as that of the age-adjusted population. In comparison with other collagen diseases, the predisposition for the development of non-Hodgkin’s lymphoma is strikingly high in primary Sjögren’s syndrome. This paper discusses different aspects of prognosis with special consideration of the life expectancy and lymphoma development. Finally, a practical mode of long-term medical care for patients with Sjögren’s syndrome is proposed with special regard to risk stratification and intensity of long-term monitoring.

Sjögren-Syndrom - Lymphom - Prognose - Lymphomscreening - Exokrine Funktion

Sjögren’s syndrome - lymphoma - prognosis - screening for lymphoma - exocrine function

Literatur

• 1 Aasarod K, Haga H J, Berg K J. et al . Renal involvement in primary Sjögren’s syndrome.  QJM. 2000;  93 297-304
• 2 Abu-Shakra M, Buskila D, Ehrenfeld M. et al . Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies.  Ann Rheum Dis. 2001;  60 433-441
• 3 Aljurf M D, Owaidah T W, Ezzat A. et al . Antigen- and ord immune-driven lymphoproliferative disorders.  Annals of Oncology. 2003;  14 1595-1606
• 4 Amft N, Bowman S J. Chemokines and Cell Trafficking in Sjögren’s Syndrome.  Scand J Immunol. 2001;  54 62-69
• 5 Bahler D W, Miklos J A, Swerdlow S H. Ongoing Ig gene hypermutation in salivary mucosa-associated lymphoid tissue type lymphomas.  Blood. 1997;  89 3335-3344
• 6 Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity.  Curr Opin Rheumatol. 2006;  18 (2) 129-134
• 7 Binder A, Snaith M L, Isenberg D. Sjögren’s syndrome: a study of its neurological complications.  Br J Rheumatol. 1988;  27 275-280
• 8 Bossini N, Savoldi S, Franceschini F. et al . Clinical and morphological features of kidney involvement in primary Sjögren’s syndrome.  Nephrol Dial Transplant. 2001;  16 2328-2236
• 9 Chiu C H, Weisenburger D D. An update of the epidemiology of Non-Hodgkin’s lymphoma.  Clinical Lymphoma. 2003;  4 161-168
• 10 Davidson B K, Kelly C A, Griffiths I D. Primary Sjogren’s syndrome in the North East of England: a long-term follow-up study.  Rheumatology. 1999;  38 (3) 245-253
• 11 Devauchell-Pensec V, Pennec Y, Morvan J. et al . Improvement of Sjögren’s syndrome after two infusions of Rituximab (anti-CD 20).  Arthritis Care & Research. 2007;  57 310-317
• 12 Ekström Smedby K, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics.  Cancer Epidemiol Biomarkers Prev. 2006;  15 (11) 2069-2077
• 13 Ekström-Smedby K, Hjalgrim H, Askling J. et al . Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype.  J Natl Cancer Inst. 2006;  98 (1) 51-60
• 14 Franquet T, Díaz C, Domingo P. et al . Air trapping in primary Sjögren’s syndrome: correlation of expiratory CT with pulmonary function tests.  J Comput Assist Tomogr. 1999;  23 169-173
• 15 Gannot G, Lancaster H E, Fox P C. Clinical course of primary Sjogren’s syndrome: salivary, oral and serological aspects.  J Rheumatol. 2000;  27 1905-1909
• 16 Garcia-Carrasco M, Siso A, Ramos-Casals M. et al . Raynaud’s phenomenon in primary Sjögren’s syndrome. Prevalence and clinical characteristics in a series of 320 patients.  J Rheumatol. 2002;  29 726-730
• 17 Gasparotto D, De Vita S, De Re V. et al . Extrasalivary lymphoma development in Sjögren’s syndrome: Clonal evolution from parotid gland lymphoproliferation and role of local triggering.  Arthritis Rheum. 2003;  48 (11) 3181-3186
• 18 Goules A, Masouridi S, Tzioufas A G. et al . Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome.  Medicine (Baltimore). 2000;  79 241-249
• 19 Haldorsen K, Moen K, Jacobsen H. et al . Exocrine function in primary Sjögren’s syndrom. Natural course and prognostic factors.  Ann Rheum Dis Online First. 2007;  DOI: 10.1136 /ard.2007.074203
• 20 Hansen A, Reiter K, Pruss A. et al . Dissemination of a Sjogre’s syndrome associated extranodal marginal-zone B cell lymphoma: circulating lymphoma cells and invariant mutation pattern of nodal Ig heavy- and light-chain variable-region gene rearrangements.  Arthritis Rheum. 2006;  54 (1) 127-137
• 21 Harris N L, Jaffe E S, Diebold J. et al . The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997.  Histopathology. 2000;  36 (1) 69-86
• 22 Harris N L. Lymphoid proliferation of the salivary glands.  Am J Clin Pathol. 1999;  111 (1 Suppl 1) S94-S103
• 23 Hoover R N. Lymphom risk in populations with altered immunity – a search for mechanisms.  Cancer Res. 1992;  52 (Suppl 19) 5477 s-5478 s
• 24 Ioannidis J P, Vassiliou V A, Moutsopoulos H M. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome.  Arthritis Rheum. 2002;  46 (3) 741-747
• 25 Jaffe E S. Lymphoid lesions of the head and neck: a model of lymphocyte homing and lymphomagenesis.  Am J Clin Pathol. 2002;  15 255-263
• 26 Jonnson R, Kroneld U, Backman K. et al . Progression of sialadinitis in Sjogren’s syndrome.  Br J Rheumatol. 1993;  32 578-581
• 27 Kaplan M J, Ike R W. The liver is common non-exocrine target in primary Sjögren’s syndrome. A retrospective review.  BMC Gastroenterology. 2002;  2 21-29
• 28 Kassan S S, Thomas T L, Moutsopoulos H M. et al . Increased risk of lymphoma in sicca syndrome.  Ann Intern Med. 1978;  89 888-892
• 29 Kauppi M, Pukkala E, Isomäki H. Elevated incidence of hematologic malignancies in patients with Sjögren’s syndrome compared with patients with rheumatoid arthritis (Finland).  Cancer Causes and Control. 1997;  8 201-204
• 30 Kruize A A, Bijsterveld O P, Hené R J. et al . Long term course of tear gland function in patients with keratoconjunctivitis sicca and Sjögren’s syndrome.  British Journal of Ophthalmology. 1997;  81 435-438
• 31 Leandro M J, Isenberg D A. Rheumatic disease and malignancy – is there an association?.  Scand J Rheum. 2001;  30 185-188
• 32 Lodde B M, Sankar van V, Kok M R. et al . Serum lipid levels in Sjögren’s syndrome.  Rheumatology. 2006;  45 481-484
• 33 Looney R J. Will targeting B cells be the answer for Sjogren’s syndrome?.  Arthritis Rheum. 2007;  56 1371-1377
• 34 Lopate G, Pestronk A, Al-Lozi M. et al . Peripheral neuropathy in an outpatient cohort of patients with Sjögren’s syndrome.  Muscle Nerve. 2006;  33 672-676
• 35 Manthorpe R, Manthorpe T. Das primäre Sjögren-Syndrom – Epidemiologie und Prognose.  Akt Rheumatol. 2005;  30 27-31
• 36 Manthorpe R. Wie klassifizieren wir Patienten, bei denen wir ein Sjögren-Syndrom vermuten?.  Akt Rheumatol. 2005;  30 32-37
• 37 Mariette X. Lymphomas in patients with Sjogren’s syndrome: review of the literature and physiopathologic hypothesis.  Leuk Lymphoma. 1999;  33 (1-2) 93-99
• 38 Martens P B, Pillemer S R, Jacobson L T. et al . Survivorship in a population based cohort of patients with Sjogren’s syndrome, 1976-1992.  J Rheumatol. 1999;  26 (6) 1296-1300
• 39 Masaki Y, Sugai S. Lymphoproliferative disorder in Sjögren’s syndrome.  Autoimmunity Review. 2004;  3 175-182
• 40 Mori K, Iijima M, Koike H. et al . The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy.  Brain. 2005;  128 2518-2534
• 41 Moutsopoulos H M, Andonopoulos A P. Sjögren’s syndrome: a human model of autoimmunity and malignancy.  Rheumatology. 1988;  27 253-257
• 42 National Cancer Institute . Adult Non-Hodgkin’s Lymphoma Treatment (PDQ®):.  , (http://www.cancer.gov/cancertopics/pdq/treatment/adult-non-hodgkins/healthprofessional/allpages); letzte Modifikation 11.2.2007
• 43 Ognenovski V M, Marder W, Somers E C. et al . Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophasphaide.  J Rheum. 2004;  31 1763-1767
• 44 Papiris S A, Maniati M, Constantopoulos S H. Lung involvement in primary Sjögren’s syndrome is mainly related to the small airway disease.  Ann Rheum Dis. 1999;  58 61-64
• 45 Pertovaara M, Korpela M, Kouri T. et al . The occurrence of renal involvement in primary Sjögren’s syndrome: a study of 78 patients.  Rheumatology. 1999;  38 1113-1120
• 46 Pertovaara M, Korpela M, Kouri T. et al . The occurrence of renal involvement in primary Sjögren’s syndrome: a study of 78 patients.  Rheumatology. 1999;  38 1113-1120
• 47 Pertovaara M, Korpela M, Saarelainen S. et al . Long-term follow-up study of pulmonary findings in patients with primary Sjögren’s syndrome.  Scand J Rheumatol. 2004;  33 343-348
• 48 Pertovaara M, Korpela M, Uusitalo H. et al . Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both).  Ann Rheum Dis. 1999;  58 423-427
• 49 Pijpe J, Kalk W W, Bootsma H. et al . Progression of salivary gland dysfunction in patients with Sjogren’s syndrome.  Ann Rheum Dis. 2007;  66 107-112
• 50 Pijpe J, Imhoff G W, Vissink van A. et al . Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren’s syndrome and associated MALT lymphoma.  Ann Rheum Dis. 2005;  64 958-960
• 51 Plesivcnik Novljan M, Rozman B, Hocevar A. et al . Incidence of primary Sjögren’s syndrome in Slovenia.  Ann Rheum Dis. 2004;  63 874-876
• 52 Plessivcnik Novljan M, Rozman B, Jerše M. et al . Comparison of the different classification criteria set for primary Sjögren’s syndrome.  Scand J Rheumatol. 2006;  6 463-467
• 53 Ramos-Casals M, Anaya J M, García-Carrasco M. et al . Cutaneous vasculitis in primary Sjögren syndrome. Classification and clinical significance of 52 patients.  Medicine. 2004;  83 96-106
• 54 Ramos-Casals M, Brito-Zeron P. Emerging biological therapies in primary Sjogren’s syndrome.  Rheumatology. 2007;  46 1389-1396
• 55 Ramos-Casals M, De Vita S, Tzioufas A G. Hepatitis C virus, Sjögren’s syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer.  Autoimmun Rev. 2005;  4 (1) 8-15
• 56 Ramos-Casals M, Font J, Garcia-Carrasco M. et al . Primary Sjögren syndrome: hematologic patterns of disease expression.  Medicine. 2002;  81 281-292
• 57 Ramos-Casals M, Tsioufas A G, Font G. Primary Sjögren’s syndrom: new clinical and therapeutic concepts.  Ann Rheum Dis. 2005;  64 347-354
• 58 Rogers S J, Williams C S, Romám G C. Myelopathy in Sjögren’s syndrome.  Drugs. 2004;  64 123-132
• 59 Salomonsson S, Jonsson M V, Skarstein K. et al . Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren’s syndrome.  Arthritis Rheum. 2003;  48 (11) 3187-3201
• 60 Seror R, Sordet C, Guillevin L. et al . Tolerance and efficacy of Rituximab and changes in serum B cell biomarkers in patients mit systemic complications of primary Sjögren’s syndrome.  Ann Rheum Dis. 2007;  66 351-357
• 61 Seve P, Gachon E, Petiot P. et al . Successful treatment with rituximab in a patient with mental nerve neuropathy in primary Sjogren’s syndrome.  Rheumatol Int. 2007;  28 175-177
• 62 Skopouli F N, Dafni U, Ioannidis J P. et al . Clinical evaluation, and morbidity and mortality of primary Sjögren’s syndrome.  Semin Arthritis Rheum. 2000;  29 467-472
• 63 Skoupouli F N. Kidney injury in Sjögren’s syndrome.  Nephrol Dial Transplant. 2001;  16 (Suppl 6) 63-64
• 64 Sugai S, Masaki Y, Dong L. Lymphoproliferative disorders in patients with Sjögren’s syndrome.  Autoimmun Rev. 2004;  3 (Suppl 1) S67-S69
• 65 Sutcliffe N, Inanc M, Speight P. et al . Predictors of Lymphoma development in primary Sjögren’s syndrome.  Semin Arthritis Rheum. 1998;  28 (2) 80-87
• 66 Talal N, Bunim J J. The development of malignant lymphoma in the course of Sjögren’s syndrome.  Am J Med. 1964;  36 529-540
• 67 Thanou-Stavraki A, James J A. Primary Sjogren’s Syndrome: Current and prospective therapies.  Semin Arthritis Rheum. 2007;  (ahead of print) DOI: 10.1016 /j.semarthrit.2007.06.002
• 68 Theander E, Andersson S I, Manthorpe R. et al . Proposed core set of outcome measures in patients with primary Sjogren’s syndrome: 5 years follow up.  J Rheumatol. 2005;  32 1495-1502
• 69 Theander E, Henriksson G, Ljungberg O. et al . Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors.  Ann Rheum Dis. 2006;  65 796-803
• 70 Theander E, Manthorpe R, Jacobsson L TH. Mortality and causes of death in primary Sjögren’s syndrome.  Arthritis Rheum. 2004;  50 (4) 1262-1269
• 71 Touma Z, Sayad J, Arayssi T. Successful treatment of Sjogren’s syndrome with Rituximab.  Scand J Rheumatol. 2006;  35 323-325
• 72 Tzioufas A G, Katisikis P D, Youinou P Y. et al . Sjogren’s syndrome: an oligoclonal B cell process.  Clin Exp Rheumatol. 1990;  8 (Suppl 5) 17-21
• 73 Vaudo G, Bartoni Bocci E, Shoenfeld Y. et al . Precocious intima-media thickening in patients with primary Sjögren’s syndrome.  Arthritis Rheum. 2005;  52 (12) 3890-3897
• 74 Voulgarelis M, Dafni U, Isenberg D I. et al . Malignant lymphoma in primary Sjögren’s syndrome.  Arthritis Rheum. 1999;  42 1765-1772
• 75 Voulgarelis M, Giannouli S, Anagnostou D. et al . Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren’s syndrome-associated B-cell aggressive non-Hodgkin’s lymphomas.  Hematology. 2004;  43 1050-1053
• 76 Voulgarelis M, Gianouli S, Tzioufas A G. et al . Long term remission of Sjogren’s syndrome associated aggressive B cell non-Hodgkin’s lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, predinisone).  Ann Rheum Dis. 2006;  65 (8) 1033-1037
• 77 Yamout B, El-Hajj T, Barada W. et al . Successful treatment of refractory neuroSjogren with Rituximab.  Lupus. 2007;  16 521-523
• 78 Zintzaras E, Voulgarelis M, Moutsopoulos H M. The risk of lymphoma development in autoimmune diseases: a meta-analysis.  Arch Intern Med. 2005;  165 (20) 2337-2344